Common Contracts
3 similar null contracts by ARYx Therapeutics, Inc., Avalanche Biotechnologies, Inc., Quark Pharmaceuticals Inc
AVALANCHE BIOTECHNOLOGIES, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCKAvalanche Biotechnologies, Inc. • May 30th, 2014 • Biological products, (no disgnostic substances) • California
THIS CERTIFIES THAT, for value received, , an individual residing at , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation, with its principal office at 2749 Carolina Avenue, Redwood City, CA 94061 (the “Company”) up to [ ( )] shares of the Series A Stock of the Company (the “Preferred Stock”).
QUARK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES H PREFERRED STOCKQuark Pharmaceuticals Inc • September 24th, 2010 • Pharmaceutical preparations • California
This Certifies That, for value received, «WarrantHolder», or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Quark Pharmaceuticals, Inc., a California corporation, with its principal office at 6501 Dumbarton Circle, Fremont, California 94555 (the “Company”) up to «NumberOfShares» shares of the Series H Preferred Stock of the Company (the “Preferred Stock”).
ARYX THERAPEUTICS WARRANT TO PURCHASE SERIES C PREFERRED STOCKARYx Therapeutics, Inc. • August 30th, 2007 • California
THIS CERTIFIES THAT, for value received, Life Science Group, Inc., with its principal office at One Soundshore Drive 2/Fl., Greenwich, CT 06830, or assigns (the “Holder” or “Purchaser”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ARYx Therapeutics, a California corporation, with its principal office at 2255 Martin Avenue, Suite F, Santa Clara, CA 95050 (the “Company”) up to 34,006 shares of Series C Preferred Stock of the Company (the “Preferred Stock”), as provided herein.
